ATARA BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.23 USD | -7.53% |
|
-35.58% | -35.80% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 891.9 | 1,626 | 1,393 | 311.2 | 52.27 | 39.64 | - | - |
| Enterprise Value (EV) 1 | 632.8 | 1,125 | 1,022 | 68.24 | 0.3947 | 20.41 | -48.5 | -13.96 |
| P/E ratio | -2.9 x | -4.73 x | -4.34 x | -1.46 x | -0.2 x | -0.49 x | -0.38 x | -0.44 x |
| Yield | - | - | - | - | - | 608% | 608% | 608% |
| Capitalization / Revenue | - | - | 68.5 x | 4.9 x | 6.1 x | 0.36 x | 0.55 x | 0.42 x |
| EV / Revenue | - | - | 50.3 x | 1.07 x | 0.05 x | 0.18 x | -0.68 x | -0.15 x |
| EV / EBITDA | -2.19 x | -3.74 x | -3.09 x | -0.25 x | -0 x | -0.3 x | -1.71 x | 0.15 x |
| EV / FCF | -2.62 x | -6.07 x | -4.42 x | -0.25 x | -0 x | -0.51 x | 0.64 x | 0.35 x |
| FCF Yield | -38.1% | -16.5% | -22.6% | -402% | -49,198% | -196% | 157% | 287% |
| Price to Book | 3.22 x | 3.14 x | 5.28 x | 2.64 x | - | - | - | - |
| Nbr of stocks (in thousands) | 2,166 | 3,313 | 3,537 | 3,795 | 4,077 | 4,817 | - | - |
| Reference price 2 | 411.8 | 490.8 | 394.0 | 82.00 | 12.82 | 8.230 | 8.230 | 8.230 |
| Announcement Date | 2/27/20 | 3/1/21 | 2/28/22 | 2/8/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 20.34 | 63.57 | 8.573 | 111 | 71.47 | 94.26 |
| EBITDA 1 | -288.6 | -300.7 | -331.1 | -274.9 | -271.2 | -67.76 | 28.33 | -92.54 |
| EBIT 1 | -295.7 | -309.1 | -340.5 | -280.5 | -276 | -86.14 | -89.94 | -93.23 |
| Operating Margin | - | - | -1,673.85% | -441.25% | -3,219.48% | -77.61% | -125.84% | -98.91% |
| Earnings before Tax (EBT) 1 | -291 | -306.6 | -340.1 | -228.3 | -276.1 | -90.22 | -113.2 | -70.5 |
| Net income 1 | -291 | -306.6 | -340.1 | -228.3 | -276.1 | -89.84 | -119 | -92.73 |
| Net margin | - | - | -1,672.28% | -359.12% | -3,220.88% | -80.95% | -166.57% | -98.38% |
| EPS 2 | -141.8 | -103.8 | -90.75 | -56.00 | -65.25 | -16.94 | -21.56 | -18.62 |
| Free Cash Flow 1 | -241.4 | -185.3 | -231.1 | -274.6 | -194.2 | -40 | -76 | -40 |
| FCF margin | - | - | -1,136.19% | -431.98% | -2,265.25% | -36.04% | -106.34% | -42.43% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | 50.00 | 50.00 | 50.00 |
| Announcement Date | 2/27/20 | 3/1/21 | 2/28/22 | 2/8/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.548 | 7.314 | 51.58 | 4.459 | 0.221 | 1.226 | 0.957 | 2.138 | 4.252 | 27.36 | 37.09 | 21.05 | 25.35 | 8.362 | 9.858 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -93.4 | -88.22 | -32.13 | -84.62 | -75.54 | -75.02 | -71.41 | -69.61 | -59.96 | -31.25 | -11.32 | -24.8 | -18.79 | -40.85 | -40.13 |
| Operating Margin | -1,237.45% | -1,206.18% | -62.3% | -1,897.78% | -34,180.54% | -6,118.92% | -7,462.28% | -3,255.94% | -1,410.21% | -114.22% | -30.52% | -117.81% | -74.13% | -488.57% | -407.11% |
| Earnings before Tax (EBT) 1 | -93.32 | -88.1 | 18.47 | -84.08 | -74.57 | -74.75 | -71.11 | -69.82 | -60.44 | -31.73 | -6.701 | -34.88 | -16.96 | -40.85 | -40.13 |
| Net income 1 | -93.35 | -88.1 | 18.47 | -84.09 | -74.57 | -74.77 | -71.11 | -69.8 | -60.45 | -31.75 | -7.679 | -29.25 | -21.26 | -40.85 | -40.13 |
| Net margin | -1,236.74% | -1,204.61% | 35.8% | -1,885.87% | -33,742.99% | -6,098.78% | -7,430.3% | -3,264.59% | -1,421.68% | -116.07% | -20.7% | -138.94% | -83.86% | -488.57% | -407.11% |
| EPS 2 | -24.00 | -21.75 | 4.500 | -20.50 | -18.00 | -18.00 | -17.00 | -16.50 | -14.00 | -5.750 | -1.562 | -5.250 | -4.250 | -6.750 | -6.750 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/5/22 | 8/8/22 | 11/8/22 | 2/8/23 | 5/8/23 | 8/8/23 | 11/1/23 | 3/28/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 259 | 501 | 371 | 243 | 51.9 | 19.2 | 88.1 | 53.6 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -241 | -185 | -231 | -275 | -194 | -40 | -76 | -40 |
| ROE (net income / shareholders' equity) | -92.4% | -81.4% | -91.7% | -54.1% | - | - | - | - |
| ROA (Net income/ Total Assets) | -79.2% | -65.9% | -64.4% | -112% | - | - | - | - |
| Assets 1 | 367.4 | 465.6 | 528.1 | 203.1 | - | - | - | - |
| Book Value Per Share | 128.0 | 156.0 | 74.60 | 31.00 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 5.73 | 4.51 | 10.6 | 4.19 | 1.22 | 0.4 | 8 | 10 |
| Capex / Sales | - | - | 52.02% | 6.6% | 14.27% | 0.36% | 11.19% | 10.61% |
| Announcement Date | 2/27/20 | 3/1/21 | 2/28/22 | 2/8/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.23
USD
Average target price
104.4
USD
Spread / Average Target
+1,168.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.80% | 39.64M | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B | |
| +119.39% | 10.96B |
- Stock Market
- Equities
- ATRA Stock
- Financials Atara Biotherapeutics, Inc.
